Valuation
- Market cap
- 6,266,606,000
- Revenue TTM
- $15,000,000
- Net income TTM
- $-197,530,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -1,316.87%
- Debt to equity
- 0.23
Trading
- Volume
- 11,330,400
- Avg volume
- 1,996,130
- Day's range
- $40.00 – $40.56
- Shares out
- 154,731,000
- Stochastic %K
- 93%
- Beta
- 1.11
- Analysts
- Sell
- Price target
- $42.40
Company profile
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages...
Show more
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
- Industry
- Biotechnology
- Sector
- Healthcare
- Website
- https://centessa.com
- Address
- 1 Ashley Road, 3rd Floor, Altrincham, United Kingdom
Latest news
No headlines yet.
